

VistaGen Therapeutics, Inc.  
Form 8-K  
February 07, 2014

---

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 5, 2014

Commission File Number: 000-54014

VistaGen Therapeutics, Inc.  
(Exact name of small business issuer as specified in its charter)

Nevada  
(State or other jurisdiction of incorporation or organization)  
205093315  
(IRS Employer Identification No.)

343 Allerton Avenue, South San Francisco, California 94080  
(Address of principal executive offices)

650-577-3600  
(Registrant's Telephone number)

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Changes in Fiscal Year.**

On February 5, 2014, the Board of Directors of VistaGen Therapeutics, Inc., a Nevada corporation (the "Company"), unanimously approved and adopted the Amended and Restated Bylaws of the Company (the "Amended and Restated Bylaws"), which Amended and Restated Bylaws replace the Company's previous bylaws in their entirety. A copy of the Amended and Restated Bylaws is attached to this Current Report on Form 8-K as Exhibit 3.1.

**Item 9.01 Financial Statements and Exhibits.**

See exhibit index.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: *February 7, 2014*

By: */s/ Shawn K. Singh*

---

*Name: Shawn K. Singh*

*Title: Chief Executive Officer*

---

Exhibit Index

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-3.1	Amended and Restated Bylaws of VistaGen Therapeutics, Inc.